View Filing Data

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2019, 2018, and 2017, and asset information as of December 31, 2019 and 2018:

	Years Ended December 31,
	2019		2018			2017
Net revenues:
OSUR	$	78,225	$	85,635		$	91,965
DNAG		76,380		96,108			75,099
Total	$	154,605	$	181,743		$	167,064
Operating income (loss):
OSUR	$	154	$	(15,188	)	$	(1,685	)
DNAG		18,457		43,617			41,923
Total	$	18,611	$	28,429		$	40,238
Depreciation and amortization:
OSUR	$	3,039	$	3,755		$	3,170
DNAG		4,300		3,467			3,232
Total	$	7,339	$	7,222		$	6,402
Capital expenditures:
OSUR	$	6,073	$	4,893		$	2,752
DNAG		3,241		1,451			1,585
Total	$	9,314	$	6,344		$	4,337

	December 31,
	2019		2018
Total assets:
OSUR	$	163,943	$	190,178
DNAG		185,352		125,393
Total	$	349,295	$	315,571

Presentation of Total Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:

	December 31,
	2019		2018
United States	$	23,846	$	18,776
Canada		5,697		5,192
Other regions		796		331
	$	30,339	$	24,299

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 75,715	$ 88,438
Short-term investments	80,623	68,134
Accounts receivable, net of allowance for doubtful accounts of $2,666 and $418	36,948	34,842
Inventories	23,155	22,888
Prepaid expenses	2,433	1,925
Other current assets	5,676	3,085
Total current assets	224,550	219,312
Noncurrent Assets:
Property, plant and equipment, net	30,339	24,299
Operating right-of-use assets, net	4,996
Finance right-of-use assets, net	1,951
Intangible assets, net	14,674	5,137
Goodwill	36,201	18,521
Long-term investments	33,420	44,752
Other noncurrent assets	3,164	3,550
Total noncurrent assets	124,745	96,259
TOTAL ASSETS	349,295	315,571
Current Liabilities:
Accounts payable	9,567	10,598
Deferred revenue	3,713	3,521
Accrued expenses	14,288	13,861
Finance lease liability	613
Operating lease liability	1,032
Acquisition-related contingent consideration obligation	3,500
Total current liabilities	32,713	27,980
Noncurrent Liabilities:
Finance lease liability	1,372
Operating lease liability	4,206
Acquisition-related contingent consideration obligation	112
Other noncurrent liabilities	2,848	3,312
Deferred income taxes	899	901
Total noncurrent liabilities	9,437	4,213
TOTAL LIABILITIES	42,150	32,193
COMMITMENTS AND CONTINGENCIES (Note 15)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 61,731 and 61,276 shares issued and outstanding	0	0
Additional paid-in capital	401,814	401,273
Accumulated other comprehensive loss	(12,136)	(18,706)
Accumulated deficit	(82,533)	(99,189)
Total stockholders' equity	307,145	283,378
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 349,295	$ 315,571

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME	$ 16,656	$ 20,396	$ 30,948
OTHER COMPEHENSIVE INCOME (LOSS)
Currency translation adjustments	5,767	(8,003)	4,433
Unrealized gain (loss) on marketable securities	803	(363)	(553)
COMPREHENSIVE INCOME	$ 23,226	$ 12,030	$ 34,828

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Net [Abstract]
Raw materials	$ 14,168	$ 14,092
Work in process	643	544
Finished goods	8,344	8,252
Inventories	$ 23,155	$ 22,888

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 36,417
2030 - 2034 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	22,653
2035 - 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	12,055
Non Expiring
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 1,709

The Company

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	THE COMPANY:

Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory and bioinformatics services.

Our OSUR diagnostic products include tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. We also previously manufactured and sold medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products were sold in both professional and OTC markets in North America, Europe, Central and South America, and Australia. We sold the assets associated with our cryosurgical systems business to a third party in August 2019. See further discussion at Note 4.

Our DNAG or molecular collection systems business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), CoreBiome Inc. (“CoreBiome”), Novosanis NV (“Novosanis”), and Diversigen, Inc. (“Diversigen”). DNAG’s specimen collection devices provide all-in-one systems for the collection, stabilization, transportation and storage of nucleic acids from human saliva and other sample types for genetic and microbiome applications. CoreBiome and Diversigen provide laboratory and bioinformatics services. Novosanis’ Colli-Pee collection device is designed for the volumetric collection of first-void urine for use in research, screening and diagnostics for the liquid biopsy and sexually transmitted infection markets. We also sell research use only sample collection products into the microbiome market and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide in the research, healthcare, pharmaceutical and agricultural communities.

Leases - Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 903
2020	902
2021	877
2022	850
2023	506
Thereafter	737
Total	$ 4,775

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance \| shares	1,083
Options, Granted \| shares	215
Options, Exercised \| shares	(27)
Options, Expired \| shares	(41)
Options, Forfeited \| shares	(37)
Options, Outstanding, Ending Balance \| shares	1,193
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance \| $ / shares	$ 10.19
Options, Vested or expected to vest \| shares	1,193
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	$ 12.71
Options, Exercisable \| shares	896
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	$ 7.17
Weighted-Average Exercise Price Per Share, Expired \| $ / shares	8.68
Weighted-Average Exercise Price Per Share, Forfeited \| $ / shares	13.05
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance \| $ / shares	10.68
Weighted-Average Exercise Price Per Share, Vested or expected to vest \| $ / shares	10.68
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 9.79
Weighted-Average Remaining Contractual Term, Outstanding	5 years 10 months 20 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	5 years 10 months 20 days
Weighted-Average Remaining Contractual Term, Exercisable	4 years 11 months 26 days
Aggregate Intrinsic Value, Outstanding \| $	$ 651
Aggregate Intrinsic Value, Vested or expected to vest \| $	651
Aggregate Intrinsic Value, Exercisable \| $	$ 630

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - USD ($) $ in Thousands			12 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2019	Dec. 31, 2018
Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Estimated Useful Life				7 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Estimated Useful Life			10 years	10 years
Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Estimated Useful Life				15 years
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 8,400
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 5,000
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 2,200
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 1,200
Acquired intangibles, Estimated Useful Life		8 years 4 months 2 days
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 3,560
Diversigen, Inc. [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,900
Acquired intangibles, Estimated Useful Life	10 years
Diversigen, Inc. [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 660
Acquired intangibles, Estimated Useful Life	9 years

Accrued Expenses

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Accrued Expenses

8.	ACCRUED EXPENSES:

	December 31,
	2019		2018
Payroll and related benefits	$	6,088	$	8,926
Professional fees		2,769		1,541
Income taxes payable		—		1,447
Other		5,431		1,947
	$	14,288	$	13,861

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2019
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5 years 2 months 15 days
Weighted-average remaining lease term—finance leases	3 years 5 months 12 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.31%
Weighted-average discount rate—finance leases	4.40%

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net revenues									$ 154,605	$ 181,743	$ 167,064
Operating income (loss)	$ 4,085	$ 13,052	$ 5,285	$ (3,811)	$ 12,512	$ 10,857	$ 5,558	$ (498)	18,611	28,429	40,238
Depreciation and amortization									7,339	7,222	6,402
Capital expenditures									9,314	6,344	4,337
Total assets	349,295				315,571				349,295	315,571
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									78,225	85,635	91,965
Operating income (loss)									154	(15,188)	(1,685)
Depreciation and amortization									3,039	3,755	3,170
Capital expenditures									6,073	4,893	2,752
Total assets	163,943				190,178				163,943	190,178
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									76,380	96,108	75,099
Operating income (loss)									18,457	43,617	41,923
Depreciation and amortization									4,300	3,467	3,232
Capital expenditures									3,241	1,451	$ 1,585
Total assets	$ 185,352				$ 125,393				$ 185,352	$ 125,393

Quarterly Data - Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 49,668	$ 35,989	$ 38,826	$ 30,122	$ 50,246	$ 45,885	$ 43,625	$ 41,987
Costs and expenses	45,583	22,937	33,541	33,933	37,734	35,028	38,067	42,485
Operating income	4,085	13,052	5,285	(3,811)	12,512	10,857	5,558	(498)	$ 18,611	$ 28,429	$ 40,238
Other income, net	477	1,195	524	524	1,629	510	736	412	2,720	3,287	794
Income before income taxes	4,562	14,247	5,809	(3,287)	14,141	11,367	6,294	(86)	21,331	31,716	41,032
Income tax expense	2,124	1,169	1,411	(29)	3,843	3,271	2,173	2,033	4,675	11,320	10,084
NET INCOME	$ 2,438	$ 13,078	$ 4,398	$ (3,258)	$ 10,298	$ 8,096	$ 4,121	$ (2,119)	$ 16,656	$ 20,396	$ 30,948
Earnings (loss) per share
Basic	$ 0.04	$ 0.21	$ 0.07	$ (0.05)	$ 0.17	$ 0.13	$ 0.07	$ (0.03)	$ 0.27	$ 0.33	$ 0.52
Diluted	$ 0.04	$ 0.21	$ 0.07	$ (0.05)	$ 0.16	$ 0.13	$ 0.07	$ (0.03)	$ 0.27	$ 0.33	$ 0.51

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	661,000
Shares, Granted	201,000
Performance adjustment	168,000
Shares, Vested	(505,000)	0
Shares, Issued and unvested, Ending Balance	525,000	661,000
Shares, Issued and expected to vest	525,000
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 9.26
Weighted-Average Grant Date Fair Value, Granted	12.98
Weighted-Average Grant Date Fair Value, Performance adjustment	12.98
Weighted-Average Grant Date Fair Value, Vested	5.47
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	12.52	$ 9.26
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 12.52

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 77,221	$ 67,096
Less accumulated depreciation	(46,882)	(42,797)
Property plant and equipment Net	30,339	24,299
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	23,231	22,480
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	33,568	29,017
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	11,590	9,632
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	2,791	2,681
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 4,923	$ 2,168

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current
Federal									$ 0	$ 0	$ 0
State									1,033,000	155,000
Foreign									5,099,000	12,084,000	10,733,000
Total current income tax expense (benefit)									6,132,000	12,239,000	10,733,000
Deferred
Federal									3,568,000	9,200,000	10,297,000
State									125,000	1,011,000	(827,000)
Foreign									(697,000)	(919,000)	(649,000)
Total deferred income tax expense (benefit)									2,996,000	9,292,000	8,821,000
Decrease in valuation allowance					$ (11,273,000)				(4,453,000)	(10,211,000)	(9,470,000)
Deferred income taxes									(1,457,000)	(919,000)	(649,000)
Total income tax expense	$ 2,124,000	$ 1,169,000	$ 1,411,000	$ (29,000)	$ 3,843,000	$ 3,271,000	$ 2,173,000	$ 2,033,000	$ 4,675,000	$ 11,320,000	$ 10,084,000

Quarterly Data

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data

17.	QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2019 and 2018. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.

	2019 Results
	Three months ended
	March 31, 2019			June 30, 2019		September 30, 2019				December 31, 2019

Net revenues	$	30,122		$	38,826	$	35,989			$	49,668
Costs and expenses		33,933			33,541		22,937	(1	)		45,583
Operating income (loss)		(3,811	)		5,285		13,052	(1	)		4,085
Other income, net		524			524		1,195				477
Income (loss) before income taxes		(3,287	)		5,809		14,247				4,562
Income tax expense		(29	)		1,411		1,169				2,124
Net income (loss)	$	(3,258	)	$	4,398	$	13,078			$	2,438
Earnings (loss) per share
Basic	$	(0.05	)	$	0.07	$	0.21			$	0.04
Diluted	$	(0.05	)	$	0.07	$	0.21			$	0.04


	2018 Results
	Three months ended
	March 31, 2018			June 30, 2018		September 30, 2018				December 31, 2018

Net revenues	$	41,987		$	43,625	$	45,885			$	50,246
Costs and expenses		42,485			38,067		35,028				37,734
Operating income		(498	)		5,558		10,857				12,512
Other income, net		412			736		510				1,629
Income before income taxes		(86	)		6,294		11,367				14,141
Income tax expense		2,033			2,173		3,271				3,843
Net income	$	(2,119	)	$	4,121	$	8,096			$	10,298

Earnings per share
Basic	$	(0.03	)	$	0.07	$	0.13			$	0.17
Diluted	$	(0.03	)	$	0.07	$	0.13			$	0.16

⁽¹⁾ Includes a $10,149 gain associated with the sale of the cryosurgical business, which was recorded as a reduction of operating expenses in the indicated period.

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
NET INCOME	$ 2,438	$ 13,078	$ 4,398	$ (3,258)	$ 10,298	$ 8,096	$ 4,121	$ (2,119)	$ 16,656	$ 20,396	$ 30,948
Weighted average shares of common stock outstanding:
Basic									61,675	61,112	59,050
Dilutive effect of stock options, restricted stock, and performance stock units									495	1,420	1,974
Diluted									62,170	62,532	61,024
Basic	$ 0.04	$ 0.21	$ 0.07	$ (0.05)	$ 0.17	$ 0.13	$ 0.07	$ (0.03)	$ 0.27	$ 0.33	$ 0.52
Diluted	$ 0.04	$ 0.21	$ 0.07	$ (0.05)	$ 0.16	$ 0.13	$ 0.07	$ (0.03)	$ 0.27	$ 0.33	$ 0.51

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2020	$ 685
2021	556
2022	555
2023	325
2024	17
Thereafter	4
Total Minimum Finance Lease Payments	2,142
Less: imputed interest	(157)
Present Value of Finance Lease Liabilities	1,985
Operating Lease Liabilities, Payments Due [Abstract]
2020	1,273
2021	1,214
2022	1,194
2023	759
2024	777
Thereafter	760
Total Minimum Operating Lease Payments	5,977
Less: imputed interest	(739)
Present Value of Operating Lease Liabilities	$ 5,238

Retirement Plans

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Retirement Plans

16.	RETIREMENT PLANS:

Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $754, $721 and $617 to the 401(k) Plan, net of forfeitures, in 2019, 2018, and 2017, respectively.

In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2019 and 2018, the value of the assets associated with this plan was $3,519 and $3,884, respectively, and is included in current assets and other assets in our consolidated balance sheets. Our

obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in our consolidated balance sheets. As of December 31, 2019 and 2018, our total obligation under this plan was $3,519 and $3,884, respectively.

Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed $184, $163 and $145 to the RRSP in 2019, 2018, and 2017, respectively.

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - Corebiome Inc. Diversign and Novosanis NV [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Revenue	$ 158,576	$ 190,487	$ 173,554
Net income	$ 16,806	$ 19,448	$ 27,436
Net income per share, basic	$ 0.27	$ 0.32	$ 0.46
Net income per share, diluted	$ 0.27	$ 0.31	$ 0.45

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill Roll Forward
Beginning Balance	$ 18,521	$ 20,083
Goodwill acquired during the year	16,811
Change related to foreign currency translation	869	(1,562)
Ending Balance	$ 36,201	$ 18,521

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 38,094	$ 25,242
Intangible Assets, Accumulated Amortization	(23,420)	(20,105)
Intangible Assets, Net	$ 14,674	$ 5,137
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 14,731	$ 9,186
Intangible Assets, Accumulated Amortization	(8,054)	(6,532)
Intangible Assets, Net	$ 6,677	$ 2,654
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 5,400	$ 5,400
Intangible Assets, Accumulated Amortization	(5,158)	(4,708)
Intangible Assets, Net	242	$ 692
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)		7 years
Intangible Assets, Gross	12,410	$ 7,135
Intangible Assets, Accumulated Amortization	(7,982)	$ (7,135)
Intangible Assets, Net	$ 4,428
Developed Technology [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years
Developed Technology [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)		15 years
Intangible Assets, Gross	$ 5,553	$ 3,521
Intangible Assets, Accumulated Amortization	(2,226)	(1,730)
Intangible Assets, Net	$ 3,327	$ 1,791
Tradename [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Tradename [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets Acquired
Goodwill	$ 36,201			$ 18,521	$ 20,083
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable			$ 791
Inventories			310
Other current assets			82
Property, plant, and equipment, net			414
Other assets			5
Acquired intangible assets			8,400
Goodwill			10,368
Total assets acquired			20,370
Liabilities Assumed
Current liabilities			1,180
Notes payable, short-term			730
Deferred tax liability			819
Other long-term liabilities			74
Total liabilities assumed			2,803
Net Assets Acquired			17,567
Estimated fair value of contingent consideration			(4,350)
Net Cash Paid			13,217
Net Cash Paid			$ 13,217
Diversigen, Inc. [Member]
Assets Acquired
Accounts receivable		$ 1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,443
Total assets acquired		13,198
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,584
Estimated fair value of contingent consideration		0
Net Cash Paid		10,584
Net Cash Paid		$ 10,584

Leases - Summary of Components of Lease Expense (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Lease Cost [Abstract]
Operating Lease Cost	$ 964
Finance Lease Cost
Amortization of right-of use assets	410
Interest on lease liabilities	36
Total Finance Lease Cost	$ 446

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 9,897	$ 10,812
Inventories	2,002	1,005
Capitalized research and development costs	1,183	1,697
Accruals and reserves currently not deductible	2,272	3,767
Acquired intangible assets	(3,525)	(1,153)
Depreciation and amortization	(1,999)	(1,082)
Stock-based compensation	1,777	1,248
Tax credit carryforwards	2,055	1,819
Net deferred tax asset	13,662	18,113
Valuation allowance	(14,561)	(19,014)
Net deferred tax liability	$ (899)	$ (901)

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

11.	INCOME TAXES:

Income before income tax expense consists of the following:

	Years Ended December 31,
	2019		2018			2017
United States	$	3,106	$	(11,728	)	$	2,270
Foreign		18,225		43,444			38,762
	$	21,331	$	31,716		$	41,032

The components of income tax expense are as follows:

	Years Ended December 31,
	2019			2018			2017
Current
Federal	$	—		$	—		$	—
State		1,033			155			—
Foreign		5,099			12,084			10,733
		6,132			12,239			10,733
Deferred
Federal		3,568			9,200			10,297
State		125			1,011			(827	)
Foreign		(697	)		(919	)		(649	)
		2,996			9,292			8,821
Decrease in valuation allowance		(4,453	)		(10,211	)		(9,470	)
		(1,457	)		(919	)		(649	)
Total income tax expense	$	4,675		$	11,320		$	10,084

For the years ended December 31, 2019, 2018, and 2017 we recorded foreign income tax expense of $4,607, $11,165, and $10,084, respectively.

The Tax Cuts and Jobs Act

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Tax Act”) that instituted fundamental changes to the taxation on multinational corporations. Although the Tax Act is generally effective January 1, 2018, U.S. generally accepted accounting principles requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. Among the numerous provisions, the Tax Act includes three provisions in particular which require consideration for financial reporting: a permanent reduction in the corporate tax rate to 21%, a one-time tax on undistributed foreign earnings, and a new U.S. tax on global intangible low taxed income (“GILTI”) which is a tax on certain earnings of foreign affiliates.

The reduction in the U.S. corporate tax rate to 21% became effective in 2018. This change resulted in a re-measurement of our net deferred tax balance at the end of 2017 with no net financial statement impact due to a comparable decrease in our deferred tax valuation allowance.

The one-time tax on undistributed and previously untaxed post-1986 foreign earnings and profits (E&P) of foreign affiliates owned by U.S. shareholders as of December 31, 2017 was analyzed for our Canadian subsidiary. For the 2017 federal tax return filed during 2018 our U.S. federal taxable loss exceeded and offset the provisional mandatory repatriation net inclusion and as such, no additional taxes were due as a result of the deemed repatriation of these foreign earnings.

In addition, the Tax Act also included changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion and promote U.S. production. The Tax Act also included repeal of the corporate alternative minimum tax, expensing of capital investment, changes to the Federal net operating loss (“NOL”) utilization and carryforward rules, and limitations of the deduction for interest expense and certain employee compensation.

As a result of the complex impact of the Tax Act, the SEC provided guidance under Staff Accounting Bulletin No. 118 (“SAB 118”) that allowed the Company to record provisional amounts as of December 31, 2017 for the impact of the Tax Act, provided that the provisional amounts could be reasonably determined and with the requirement that the final accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2018, the Company has completed the accounting for the tax effects of the Tax Act, and therefore, has recorded final amounts which include:

(a)

The impact of the one-time transition tax on existing net operating loss and foreign tax credit carryforwards generated, as well as the related offsetting valuation allowances. The final one-time transitioned income reported on the 2017 federal tax return filed in 2018 was $17,724. This amount decreased both the net operating loss carryforward as well as the corresponding valuation allowance. Based on updated guidance, in 2018 the Company elected to deduct foreign taxes and therefore did not generate foreign tax credits. As such the deferred tax asset recorded as of December 31, 2017 associated with foreign tax credits was reversed in 2018.

(b)

The valuation allowance for the Company’s deferred tax assets as of December 31, 2017, was primarily dependent on forecasted future taxable income in the U.S. and Canada and was impacted by the provisions of the Tax Act. The primary impact of the Tax Act was the lowering of the statutory rate to 21%. This lowered the deferred tax assets and corresponding valuation allowance by $11,273.

The Tax Act imposed a U.S. tax on GILTI that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. The GILTI computation for 2018 was completed and is reflected in the 2018 income tax provision. The Company has made a policy election related to its treatment of GILTI and will treat it as a current period expense in the reporting period in which the tax is incurred.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2019, 2018, and 2017 is as follows:

	2019				2018				2017
Statutory U.S. federal income tax rate		21.0		%		21.0		%		34.0		%
Deemed repatriation tax		—				10.9				7.8
GILTI tax		16.9				22.2				—
Statutory rate change, deferred tax impact		—				—				29.4
Nondeductible executive compensation		0.4				4.8				—
Impact of share-based payment awards		(5.3	)			0.6				(16.0	)
Tax effect of foreign items		4.5				6.8				(8.3	)
State income taxes, net of federal benefit		4.0				2.8				(1.1	)
Nondeductible transaction costs		1.6				—				—
Nondeductible expenses and other		(0.7	)			(1.2	)			1.9
Change in valuation allowance, federal and state		(20.5	)			(32.2	)			(23.1	)
Effective tax rate		21.9		%		35.7		%		24.6		%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2019 and 2018 are as follows:

	2019			2018
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	9,897		$	10,812
Inventories		2,002			1,005
Capitalized research and development costs		1,183			1,697
Accruals and reserves currently not deductible		2,272			3,767
Acquired intangible assets		(3,525	)		(1,153	)
Depreciation and amortization		(1,999	)		(1,082	)
Stock-based compensation		1,777			1,248
Tax credit carryforwards		2,055			1,819
Net deferred tax asset		13,662			18,113
Valuation allowance		(14,561	)		(19,014	)
Net deferred tax liability	$	(899	)	$	(901	)

In assessing the realizability of our deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2019 and 2018 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2019, 2018, or 2017.

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2030 - 2034	$	22,653
2035 - 2037	$	12,055
Non-Expiring		1,709
	$	36,417

The accounting guidance under ASU 2016-09 allows for the recognition of excess tax benefits associated with stock-based compensation awards regardless of whether the deduction reduces taxes payable. On January 1, 2017, we recorded a cumulative adjustment to retained earnings of $3,391 to recognize the increase in our net operating loss carryforwards from the cumulative excess tax benefits not recognized in periods prior to January 1, 2017. A corresponding $3,391 increase to our valuation allowance associated with this tax benefit was also recorded to retained earnings thereby resulting in no impact to retained earnings.

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. We do not believe that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. We continue to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs.

Effective January 1, 2018, there is a transition to a participation exemption system whereby distributions from foreign subsidiaries to U.S. shareholders are generally exempt from taxation. Our intention is to continue to permanently reinvest the historical undistributed earnings of our foreign subsidiary to the extent that we will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary.

As of December 31, 2019, our gross unrecognized tax benefits totaled $1,308, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2019, 2018 and 2017. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2019.

A reconciliation of our unrecognized tax benefits is as follows:

	2019			2018			2017
Balance as of January 1	$	1,676		$	1,663		$	2,084
Additions for tax positions of prior periods		4			44			-
Reductions for tax positions of prior periods		(372	)		(31	)		(421	)
Balance as of December 31	$	1,308		$	1,676		$	1,663

Transition Costs - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
General and Administrative Expenses [Member]
Transition Costs [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 9,602

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands			12 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2019
Business Acquisition [Line Items]
Net of cash acquired			$ 23,801
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Net of cash acquired		$ 103
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 479

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Purchase Obligation Fiscal Year Maturity [Abstract]
2020	$ 10,279
2021	20
2022	20
2023	18
Total	$ 10,337

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Property, Plant and Equipment

6.	PROPERTY, PLANT AND EQUIPMENT:

	December 31,
	2019			2018
Land	$	1,118		$	1,118
Buildings and improvements		23,231			22,480
Machinery and equipment		33,568			29,017
Computer equipment and software		11,590			9,632
Furniture and fixtures		2,791			2,681
Construction in progress		4,923			2,168
		77,221			67,096
Less accumulated depreciation		(46,882	)		(42,797	)
	$	30,339		$	24,299

Depreciation expense was $4,421, $3,828, and $3,434 for 2019, 2018, and 2017, respectively.

Commitments and Contingencies - Schedule of Base Salary for Continuing Employment Agreement (Detail) - Employment Agreements [Member] $ in Thousands	Dec. 31, 2019 USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
2020	$ 3,110
2021	1,682
2022	460
2023	309
Total	$ 5,561

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance \| shares	357
Shares, Granted \| shares	329
Shares, Vested \| shares	(212)
Shares, Forfeited \| shares	(10)
Shares, Issued and unvested, Ending Balance \| shares	464
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 12.14
Shares, Issued and expected to vest \| shares	464
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	$ 11.58
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	10.30
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	13.69
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	12.86
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 12.86

Business Segment Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Business Segment Information

14.	BUSINESS SEGMENT INFORMATION:

Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of CoreBiome, Novosanis and Diversigen are included in our DNAG segment. Our cryosurgical system business was included in our OSUR segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

Operating income (loss) for the year ended December 31, 2018 and 2017 has been modified to conform to the classification of the intercompany service fee presentation for 2019. Beginning with the first quarter of 2019, we have included the fees for intercompany services in our segment operating income (loss) in order to more accurately reflect the results of each segment.

The following table summarizes operating segment information for the years ended December 31, 2019, 2018, and 2017, and asset information as of December 31, 2019 and 2018:

	Years Ended December 31,
	2019		2018			2017
Net revenues:
OSUR	$	78,225	$	85,635		$	91,965
DNAG		76,380		96,108			75,099
Total	$	154,605	$	181,743		$	167,064
Operating income (loss):
OSUR	$	154	$	(15,188	)	$	(1,685	)
DNAG		18,457		43,617			41,923
Total	$	18,611	$	28,429		$	40,238
Depreciation and amortization:
OSUR	$	3,039	$	3,755		$	3,170
DNAG		4,300		3,467			3,232
Total	$	7,339	$	7,222		$	6,402
Capital expenditures:
OSUR	$	6,073	$	4,893		$	2,752
DNAG		3,241		1,451			1,585
Total	$	9,314	$	6,344		$	4,337

	December 31,
	2019		2018
Total assets:
OSUR	$	163,943	$	190,178
DNAG		185,352		125,393
Total	$	349,295	$	315,571

The following table represents total long-lived assets by geographic area:

	December 31,
	2019		2018
United States	$	23,846	$	18,776
Canada		5,697		5,192
Other regions		796		331
	$	30,339	$	24,299

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Gain on sale of business	$ 10,149
Cryosurgical Systems
Gain on sale of business	$ 10,149

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

7.	GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:

	December 31,
	2019		2018
Balance as of January 1		18,521		20,083
Goodwill acquired during the year		16,811		—
Change related to foreign currency translation		869		(1,562	)
Balance as of December 31	$	36,201	$	18,521

Intangible assets consist of the following:

			December 31, 2019
	Amortization Period (Years)		Gross		Accumulated Amortization			Net

Customer relationships		10	$	14,731	$	(8,054	)	$	6,677
Patents and product rights		10		5,400		(5,158	)		242
Developed technology	7-10			12,410		(7,982	)		4,428
Tradename	5-15			5,553		(2,226	)		3,327
			$	38,094	$	(23,420	)	$	14,674

			December 31, 2018
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	9,186	$	(6,532	)	$	2,654
Patents and product rights		10		5,400		(4,708	)		692
Developed technology		7		7,135		(7,135	)		-
Tradename		15		3,521		(1,730	)		1,791
			$	25,242	$	(20,105	)	$	5,137

Amortization expense for 2019, 2018, and 2017 was $2,522, $2,623, and $2,641, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2020		2,619
2021		2,375
2022		1,470
2023		1,470
2024		1,430
Beyond		5,310
	$	14,674

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Risk-free interest rate	2.52%	2.60%	2.22%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	41.00%	43.00%	43.00%
Expected life of stock options (in years)	5 years	6 years	7 years

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Depreciation expense	$ 4,421	$ 3,828	$ 3,434

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) Supplier shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Jan. 01, 2019 USD ($)	Jan. 01, 2018 USD ($) PerformanceObligation
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid	$ 10,611	$ 17,126	$ 4,309
Increase or decrease in allowance for doubtful accounts	2,231	(27)	172
Write-offs against allowance for doubtful accounts	110	11	200
Accruals for purchases of property and equipment	660	964	449
Accumulated deficit	(82,533)	(99,189)	(119,510)
Reserve for sales return and allowances	472	191
Deferred revenue	$ 3,713	3,521	1,314
Contract with customer payment terms, description	Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Right-of-use assets				$ 4,027
Lease liabilities				$ 4,263
Advertising expenses	$ 524	763	717
Net foreign exchange (losses) gains	(1,339)	831	$ (1,442)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	12,022	17,789
Unrealized loss on marketable securities	114	917
Cash and cash equivalents	75,715	88,438
Fair value of plan assets	3,519	3,884
Long-term Contract [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	1,809	1,464
ASU 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit					$ (119,585)
Deferred revenue					1,389
ASU 2014-09 [Member] \| Change in Revenue Recognition [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit					(75)
Deferred revenue					$ 75
Drug Testing Kit Sales [Member] \| ASU 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations \| PerformanceObligation					2
Drug Testing Kit Sales [Member] \| ASU 2014-09 [Member] \| Change in Revenue Recognition [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit					$ 75
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 1,624	$ 21,631
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares	768	291	180
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,904	$ 2,057
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	19.00%	7.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	15.00%	24.00%	25.00%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Contract with customer payment terms	120 days
Sales commissions amortization period	1 year
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2019			2018			2017
Risk-free interest rate⁽¹⁾		2.52	%		2.60	%		2.22	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		41	%		43	%		43	%
Expected life of stock options (in years)⁽²⁾		5			6			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2019			2018			2017
Total compensation cost during the year	$	1,161		$	2,163		$	2,045
Amounts capitalized into inventory during the year		(343	)		(420	)		(371	)
Amounts recognized in cost of products sold for amounts previously capitalized		405			396			276
Amounts charged against income	$	1,223		$	2,139		$	1,950

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2019		1,083			10.19
Granted		215			12.71
Exercised		(27	)		7.17
Expired		(41	)		8.68
Forfeited		(37	)		13.05
Outstanding on December 31, 2019		1,193		$	10.68		5.89	$	651
Vested or expected to vest as of December 31, 2019		1,193		$	10.68		5.89	$	651
Exercisable on December 31, 2019		896		$	9.79		4.99	$	630

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2019:

Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37 - $8.24		371		4.6	$	6.16		352	$	6.13
$8.87 - $14.95		657		6.1		10.82		432		10.08
$16.80 - $21.89		165		8.1		20.30		112		20.15
		1,193		5.9	$	10.68		896	$	9.79

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2019		357			12.14
Granted		329			11.58
Vested		(212	)		10.30
Forfeited		(10	)		13.69
Issued and unvested, December 31, 2019		464		$	12.86
Issued and expected to vest, December 31, 2019		464		$	12.86

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2019		661			9.26
Granted⁽¹⁾		201			12.98
Performance adjustment⁽²⁾		168			12.98
Vested		(505	)		5.47
Issued and unvested, December 31, 2019		525		$	12.52
Issued and expected to vest, December 31, 2019		525		$	12.52

^1.

^{Grant activity for all PSUs disclosed at target.}

^2.

^{Reflects the performance adjustment based on actual performance measured at the end of the performance period.}

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Summary of Significant Accounting Policies - Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
CURRENT LIABILITIES:
Deferred revenue	$ 3,713	$ 3,521		$ 1,314
STOCKHOLDERS' EQUITY
Accumulated deficit	$ (82,533)	$ (99,189)		$ (119,510)
ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue			$ 1,389
STOCKHOLDERS' EQUITY
Accumulated deficit			(119,585)
New Revenue Standard Adjustment [Member] \| ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue			75
STOCKHOLDERS' EQUITY
Accumulated deficit			$ (75)

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Feb. 29, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity File Number	001-16537
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Emerging Growth Company	false
Entity Small Business	false
Document Annual Report	true
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		62,002,705
Entity Public Float			$ 569,761,924
Documents Incorporated by Reference	Documents Incorporated by Reference: Portions of the Registrant’s Definitive Proxy Statement for the 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report.

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

	December 31,
	2019		2018
Payroll and related benefits	$	6,088	$	8,926
Professional fees		2,769		1,541
Income taxes payable		—		1,447
Other		5,431		1,947
	$	14,288	$	13,861

Transition Costs

12 Months Ended

Dec. 31, 2019

Transition Costs [Abstract]

Transition Costs

13.	TRANSITION COSTS

In January 2018, we announced the retirement of our President and CEO and our CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Douglas A. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Ronald H. Spair, our former CFO and Chief Operating Officer, who retired on that same date. Charges associated with these transitions were $9,602 during 2018 and are included in general and administrative expenses in the consolidated statement of income. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO.

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Total compensation cost during the year	$ 1,161	$ 2,163	$ 2,045
Amounts capitalized into inventory during the year	(343)	(420)	(371)
Amounts recognized in cost of products sold for amounts previously capitalized	405	396	276
Amounts charged against income	$ 1,223	$ 2,139	$ 1,950

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 2,666	$ 418
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	61,731,000	61,276,000
Common stock, shares outstanding	61,731,000	61,276,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
OPERATING ACTIVITIES:
Net income	$ 16,656	$ 20,396	$ 30,948
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	4,057	15,237	6,973
Depreciation and amortization	7,339	6,451	6,075
Other non-cash amortization	391	771	327
Provision for doubtful accounts	2,248	(53)	(13)
Unrealized foreign currency (gain) loss	385	(400)	156
Interest expense on finance leases	36
Deferred income taxes	(1,457)	(919)	(649)
Loss (gain) on sale of fixed assets	147		(25)
Gain on sale of business	(10,149)
Change in the estimated fair value of contingent earn-out consideration	(664)
Changes in assets and liabilities
Accounts receivable	(2,210)	6,688	(22,103)
Inventories	(1,324)	(3,857)	(7,391)
Prepaid expenses and other assets	200	(366)	(384)
Accounts payable	(1,537)	208	5,157
Deferred revenue	(297)	2,240	(93)
Accrued expenses and other liabilities	(4,017)	(7,306)	9,178
Net cash provided by operating activities	9,804	39,090	28,156
INVESTING ACTIVITIES:
Purchases of investments	(92,173)	(163,763)	(161,269)
Proceeds from maturities and redemptions of investments	93,491	152,680	69,253
Purchases of property and equipment	(9,314)	(6,344)	(4,337)
Acquisition of businesses, net of cash acquired	(23,801)
Proceeds from sale of business	12,000
Net cash used in investing activities	(19,797)	(17,427)	(96,353)
FINANCING ACTIVITIES:
Repayments of loans	(724)
Cash payments for lease liability	(442)
Proceeds from exercise of stock options	196	1,701	31,675
Repurchase of common stock	(3,712)	(3,592)	(1,240)
Net cash provided by (used in) financing activities	(4,682)	(1,891)	30,435
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	1,952	(4,203)	841
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(12,723)	15,569	(36,921)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	88,438	72,869	109,790
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	$ 75,715	$ 88,438	$ 72,869

The Company - Additional Information (Detail)	12 Months Ended
The Company - Additional Information (Detail)	Dec. 31, 2019 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, CoreBiome, Novosanis and Diversigen. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2019, 2018 and 2017, we paid income taxes of $10,611, $17,126 and $4,309, respectively.

In 2019, 2018 and 2017, we recorded through the consolidated statements of income an increase (decrease) in our allowance for doubtful accounts of $2,231, $(27) and $172, respectively. We had $110, $11 and $200 in write-offs against the allowance for doubtful accounts in 2019, 2018, and 2017, respectively.

As of December 31, 2019, 2018 and 2017, we had accruals for purchases of property and equipment of $660 , $964 and $ 449, respectively.

Investments

We consider all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of December 31, 2019 and 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At December 31, 2019, maturities of our available- for-sale securities were as follows:
Less than one year	$	80,754	$	163	$	(294	)	$	80,623
Greater than one year	$	33,403	$	108	$	(91	)	$	33,420

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage based on historical write-off rates.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and

furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, developed technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

We assess the recoverability of our long-lived assets, which include property and equipment and definite-lived intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time.

Goodwill

Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG, CoreBiome, Novosanis and Diversigen. All acquired goodwill has been allocated to our DNAG segment. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our annual impairment assessment as of July 31, 2019 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2019, we believe no indicators of impairment exist.

Revenue

In January 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, using the modified retrospective method applied to contracts existing as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance.

Upon adoption, we recorded a reduction of $75 to the opening balance of accumulated deficit as of January 1, 2018. This adjustment is related to the change in revenue recognition associated with our drug testing kit sales. Sales of our drug testing kits include two performance obligations: sales of the device and laboratory services. Under this new accounting standard, we adjusted the allocation of the transaction price to the performance obligations and the estimate of unexercised rights (“breakage”) associated with the contracts. Prior to the adoption of the new guidance, we used the residual value method to allocate the transaction prices. With the adoption of ASU 2014-09, we allocated transition prices based upon the stand-alone selling price, or fair value method. This change in methodology also impacted our estimated breakage amount.

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

The adoption of this new standard had an immaterial impact on our 2018 reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are described below.

Product Sales

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.

Our net revenues recorded for sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising and discounts. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.

Other than for sales of our OraQuick® In-Home HIV test to the retail trade and under the terms of a long-term contract with a genomics customer, we generally do not grant product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

As a result of the return rights granted to our customers for our OraQuick® In-Home HIV test, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. The amounts of returns agreed to under the long-term customer contract are based on a pre-determined percentage of revenues and as such, out estimate of expected returns is calculated in accordance with the terms of the contract. As of December 31, 2019 and December 31, 2018, the reserve for sales returns and allowances was $472 and $191, respectively.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Service Revenues

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. We recognize revenues and satisfy our performance obligation for services rendered when the testing is complete and the associated results are reported

Arrangements with Multiple-performance Obligations

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, which largely applies to our service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an observable cost plus margin approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.

Other Revenues

Other revenues. Other revenues consist primarily of royalty income, funding of research and development efforts and cost reimbursements under a charitable support agreement. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Funding and charitable support reimbursements are recorded as the activities are being performed in accordance with the respective agreements.

Deferred Revenue

We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2019 and 2018 includes customer prepayments of $1,904 and $2,057, respectively. Deferred revenue as of December 31, 2019 and 2018 also included $1,809 and $1,464, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined and revenue is recognized at that rate when the product is delivered to the customer.

Financing and Payment

Financing and Payment. Our payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical Expedients and Exemptions

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, we defer the cost of the commission and expense it over the life of the related sales contract.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2019		2018		2017
OraQuick®	$	56,064	$	53,851	$	60,558
Oragene®		46,701		69,798		67,232
ORAcollect®		10,651		6,052		1,952
Intercept®		8,105		7,709		8,125
Microbiome laboratory services		6,104		1,563		1,223
Histofreezer® (through August 16, 2019)		5,702		8,983		10,312
OMNIgene® • GUT		5,226		4,193		2,072
Other products		9,520		13,279		10,514
Net product and service revenues		148,073		165,428		161,988

Royalty income		5,116		9,653		—
Research and development funding		851		4,951		4,387
Charitable support reimbursement		261		1,711		689
Grant funding		304		—		—
Other revenues		6,532		16,315		5,076

Net revenues	$	154,605	$	181,743	$	167,064

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2019		2018		2017
United States	$	107,279	$	136,847	$	121,458
Europe		11,752		11,062		11,827
Other regions		35,574		33,834		33,779
	$	154,605	$	181,743	$	167,064

Customer and Vendor Concentrations

One of our customers accounted for 19% and 7% of our accounts receivable as of December 31, 2019 and 2018, respectively. The same customer accounted for approximately 15%, 24% and 25% of our net consolidated revenues for the year ended December 31, 2019, 2018, and 2017 respectively.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and have not restated comparative amounts. Also, we elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. Leases with an initial term of 12 months or less are not recognized on the balance sheet and the associated lease payments are included in the consolidated statements of operations on a straight-line basis over the lease term. As a result, on January 1, 2019, we recorded right-of-use assets of $4,027 and lease liabilities of $4,263 on our consolidated balance sheet.

Business Combinations and Contingent Consideration

Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires us to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although we believe the assumptions and estimates we have made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.

We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of our consideration for the CoreBiome, Novosanis, and Diversigen acquisitions, we are contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, we are required to update our underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations. Our estimates of fair value are based on assumptions we believe to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on our results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates.

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and


	•		discount rates used to determine the present value of estimated future cash flows.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2019, 2018, and 2017, we incurred $524, $763, and $717, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(1,339), $831, and $(1,442) for the years ended December 31, 2019, 2018, and 2017, respectively.

Earnings Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2019		2018		2017
Net income	$	16,656	$	20,396	$	30,948
Weighted average shares of common stock outstanding:
Basic		61,675		61,112		59,050
Dilutive effect of stock options, restricted stock, and performance stock units		495		1,420		1,974
Diluted		62,170		62,532		61,024
Earnings per share:
Basic	$	0.27	$	0.33	$	0.52
Diluted	$	0.27	$	0.33	$	0.51

For the years ended December 31, 2019, 2018, and 2017, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 768, 291, and 180 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2019 consists of $12,022 of currency translation adjustments and $114 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2018 consists of $17,789 of currency translation adjustments and $917 of net unrealized losses on marketable securities.

Fair Value of Financial Instruments

As of December 31, 2019 and 2018, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2019 and 2018.

Included in cash and cash equivalents at December 31, 2019 and 2018, was $1,624 and $21,631 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2019 and 2018 was $3,519 and $3,884, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Recent Accounting Pronouncements

In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The guidance is effective beginning in fiscal year 2020, with early adoption permitted beginning in fiscal year 2019. We have determined that this new guidance will not have a material impact on our consolidated financial statements.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. The guidance is effective in fiscal year 2020, with early adoption permitted, including adoption in an interim period. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We have determined that this new guidance will not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued guidance related to fair value measurement disclosures. This guidance removes the requirement to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy, the policy for determining that a transfer has occurred, and valuation processes for Level 3 fair value measurements. Additionally, this guidance modifies the disclosures related to the measurement uncertainty for recurring Level 3 fair value measurements (by removing the requirement to disclose sensitivity to future changes) and the timing of liquidation of investee assets (by removing the timing requirement in certain instances). The guidance also requires new disclosures for Level 3 financial assets and liabilities, including the amount and location of unrealized gains and losses recognized in other comprehensive income/(loss) and additional information related to significant unobservable inputs used in determining Level 3 fair value measurements. This guidance is effective beginning in fiscal year 2020. We have determined that this new guidance will not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued guidance related to accounting for implementation costs incurred in hosted cloud computing service arrangements. Under the new guidance, implementation costs incurred in a hosting arrangement that is a service contract should be expensed or capitalized based on the nature of the costs and the project stage during which such costs are incurred. If the implementation costs qualify for capitalization, they must be amortized over the term of the hosting arrangement and assessed for impairment. Companies must disclose the nature of any hosted cloud computing service arrangements. This guidance also provides guidance for balance sheet and income statement presentation of capitalized implementation costs and statement of cash flows presentation for the related payments. This guidance will be effective beginning in the first quarter of our fiscal year 2020. This guidance may be adopted either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We will prospectively adopt this guidance and have determined that it will not have a material impact on our consolidated financial statements.

In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification (“ASC”) 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective beginning in fiscal year 2020, with early adoption permitted beginning in fiscal year 2019. We have early-adopted this guidance and determined that this new guidance does not have a material impact on our consolidated financial statements.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income before income tax expense consists of the following:

	Years Ended December 31,
	2019		2018			2017
United States	$	3,106	$	(11,728	)	$	2,270
Foreign		18,225		43,444			38,762
	$	21,331	$	31,716		$	41,032

Components of Income Tax Expense (Benefit)

The components of income tax expense are as follows:

	Years Ended December 31,
	2019			2018			2017
Current
Federal	$	—		$	—		$	—
State		1,033			155			—
Foreign		5,099			12,084			10,733
		6,132			12,239			10,733
Deferred
Federal		3,568			9,200			10,297
State		125			1,011			(827	)
Foreign		(697	)		(919	)		(649	)
		2,996			9,292			8,821
Decrease in valuation allowance		(4,453	)		(10,211	)		(9,470	)
		(1,457	)		(919	)		(649	)
Total income tax expense	$	4,675		$	11,320		$	10,084

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2019, 2018, and 2017 is as follows:

	2019				2018				2017
Statutory U.S. federal income tax rate		21.0		%		21.0		%		34.0		%
Deemed repatriation tax		—				10.9				7.8
GILTI tax		16.9				22.2				—
Statutory rate change, deferred tax impact		—				—				29.4
Nondeductible executive compensation		0.4				4.8				—
Impact of share-based payment awards		(5.3	)			0.6				(16.0	)
Tax effect of foreign items		4.5				6.8				(8.3	)
State income taxes, net of federal benefit		4.0				2.8				(1.1	)
Nondeductible transaction costs		1.6				—				—
Nondeductible expenses and other		(0.7	)			(1.2	)			1.9
Change in valuation allowance, federal and state		(20.5	)			(32.2	)			(23.1	)
Effective tax rate		21.9		%		35.7		%		24.6		%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2019 and 2018 are as follows:

	2019			2018
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	9,897		$	10,812
Inventories		2,002			1,005
Capitalized research and development costs		1,183			1,697
Accruals and reserves currently not deductible		2,272			3,767
Acquired intangible assets		(3,525	)		(1,153	)
Depreciation and amortization		(1,999	)		(1,082	)
Stock-based compensation		1,777			1,248
Tax credit carryforwards		2,055			1,819
Net deferred tax asset		13,662			18,113
Valuation allowance		(14,561	)		(19,014	)
Net deferred tax liability	$	(899	)	$	(901	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2030 - 2034	$	22,653
2035 - 2037	$	12,055
Non-Expiring		1,709
	$	36,417

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:

	2019			2018			2017
Balance as of January 1	$	1,676		$	1,663		$	2,084
Additions for tax positions of prior periods		4			44			-
Reductions for tax positions of prior periods		(372	)		(31	)		(421	)
Balance as of December 31	$	1,308		$	1,676		$	1,663

Leases

12 Months Ended

Dec. 31, 2019

Lessee Disclosure [Abstract]

Leases

10. LEASES:

In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and will not restate comparative amounts.

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2019, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Year ended
	December 31, 2019
Operating Lease Cost	$	964
Finance Lease Cost
Amortization of right-of use assets		410
Interest on lease liabilities		36
Total Finance Lease Cost	$	446

Lease cost for the years ended December 31, 2018 and 2017 was $1,461 and $852, respectively.

Supplemental cash flow information related to leases is as follows:

	Year ended
	December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	937
Operating cash flows from financing leases		33
Financing cash flows from financing leases		442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		1,829
Right-of-use assets obtained in exchange for finance lease obligations		2,069

Right of use assets obtained include those assets acquired and entered into during 2019.

Supplemental balance sheet information related to leases is as follows:

	December 31, 2019
Operating Leases
Right-of-use assets	$	4,996

Current lease liabilities		1,032
Non-current lease liabilities		4,206
Total operating lease liabilities	$	5,238

Finance Leases
Right-of-use assets	$	1,951

Current lease liabilities		613
Non-current lease liabilities		1,372
Total finance lease liabilities	$	1,985

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.21
Weighted-average remaining lease term—finance leases	3.45

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.31	%
Weighted-average discount rate—finance leases	4.40	%

As of December 31, 2019, minimum lease payments by period are expected to be as follows:

	Finance			Operating
2020		685			1,273
2021		556			1,214
2022		555			1,194
2023		325			759
2024		17			777
Thereafter		4			760
Total Minimum Lease Payments		2,142			5,977
Less: imputed interest		(157	)		(739	)
Present Value of Lease Liabilities	$	1,985		$	5,238

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of December 31, 2019 and 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At December 31, 2019, maturities of our available- for-sale securities were as follows:
Less than one year	$	80,754	$	163	$	(294	)	$	80,623
Greater than one year	$	33,403	$	108	$	(91	)	$	33,420

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2019		2018		2017
OraQuick®	$	56,064	$	53,851	$	60,558
Oragene®		46,701		69,798		67,232
ORAcollect®		10,651		6,052		1,952
Intercept®		8,105		7,709		8,125
Microbiome laboratory services		6,104		1,563		1,223
Histofreezer® (through August 16, 2019)		5,702		8,983		10,312
OMNIgene® • GUT		5,226		4,193		2,072
Other products		9,520		13,279		10,514
Net product and service revenues		148,073		165,428		161,988

Royalty income		5,116		9,653		—
Research and development funding		851		4,951		4,387
Charitable support reimbursement		261		1,711		689
Grant funding		304		—		—
Other revenues		6,532		16,315		5,076

Net revenues	$	154,605	$	181,743	$	167,064

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2019		2018		2017
United States	$	107,279	$	136,847	$	121,458
Europe		11,752		11,062		11,827
Other regions		35,574		33,834		33,779
	$	154,605	$	181,743	$	167,064

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2019		2018		2017
Net income	$	16,656	$	20,396	$	30,948
Weighted average shares of common stock outstanding:
Basic		61,675		61,112		59,050
Dilutive effect of stock options, restricted stock, and performance stock units		495		1,420		1,974
Diluted		62,170		62,532		61,024
Earnings per share:
Basic	$	0.27	$	0.33	$	0.52
Diluted	$	0.27	$	0.33	$	0.51

ASU 2014-09 [Member]

Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

Credit Facility

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Credit Facility

9.	CREDIT FACILITY:

On March 29, 2019, we terminated our credit agreement with a commercial bank which was entered into on September 30, 2016 and had a maturity date of September 30, 2019. There were no borrowings under the credit agreement during 2019, 2018, or 2017.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

15.	COMMITMENTS AND CONTINGENCIES:

Purchase Commitments

As of December 31, 2019, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2020		10,279
2021		20
2022		20
2023		18
2024		-
	$	10,337

Employment Agreements

Under terms of employment agreements with certain employees, which extend through 2023, we are required to pay each individual a base salary for continuing employment with us as follows:

2020		3,110
2021		1,682
2022		460
2023		309
	$	5,561

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
NET REVENUES:
Total revenue	$ 154,605	$ 181,743	$ 167,064
COST OF PRODUCTS SOLD	60,022	68,130	68,108
Gross profit	94,583	113,613	98,956
OPERATING EXPENSES:
Research and development	19,629	16,250	13,365
Sales and marketing	31,869	30,609	28,532
General and administrative	35,287	38,325	29,321
Gain on litigation settlement			(12,500)
Change in the estimated fair value of acquisition-related contingent consideration	(664)
Gain on sale of business	(10,149)
Total operating expenses	75,972	85,184	58,718
Operating income	18,611	28,429	40,238
OTHER INCOME	2,720	3,287	794
Income before income taxes	21,331	31,716	41,032
INCOME TAX EXPENSE	4,675	11,320	10,084
NET INCOME	$ 16,656	$ 20,396	$ 30,948
EARNINGS PER SHARE:
BASIC	$ 0.27	$ 0.33	$ 0.52
DILUTED	$ 0.27	$ 0.33	$ 0.51
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	61,675	61,112	59,050
DILUTED	62,170	62,532	61,024
Products and Services [Member]
NET REVENUES:
Total revenue	$ 148,073	$ 165,428	$ 161,988
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 6,532	$ 16,315	$ 5,076

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2020	$ 2,619
2021	2,375
2022	1,470
2023	1,470
2024	1,430
Beyond	5,310
Intangible Assets, Net	$ 14,674	$ 5,137

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	2,534,000
Amount share repurchase program of common shares				$ 25,000,000
Total cost of common stock purchased and retired	$ 3,712,000	$ 3,592,000	$ 1,240,000
Proceeds from exercise of stock options	196,000	1,701,000	31,675,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total compensation cost	$ 4,057,000	$ 15,237,000	$ 6,973,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise periods	10 years
Vesting period	4 years
Vesting of Options	Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted	$ 5.19	$ 9.15	$ 4.71
Aggregate intrinsic value of options exercised	$ 92,000	$ 2,314,000	$ 35,631,000
Unrecognized compensation expense related to unvested option awards	$ 1,423,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 6 months
Proceeds from exercise of stock options	$ 196,000	1,701,000	31,675,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 10 months 24 days
Total compensation cost	$ 2,979,000	$ 6,357,000	$ 2,705,000
Unrecognized compensation expense related to unvested restricted stock awards	$ 3,200,000
Vesting of restricted shares, withholding and exercise obligations	76,000	171,000	130,000
Restricted shares of common stock, aggregate values	$ 949,000	$ 3,291,000	$ 1,240,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	213,000	20,000
Total cost of common stock purchased and retired	$ 2,763,000	$ 301,000
Total compensation cost	$ (83,000)	$ 6,717,000	$ 2,223,000
Performance stock units vested	505,000	0

Income Taxes - Additional Information (Detail) - USD ($)		3 Months Ended	12 Months Ended
	Jan. 01, 2017	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Foreign income tax expense			$ 4,607,000	$ 11,165,000	$ 10,084,000
Effective income tax rate		21.00%	21.00%	21.00%	34.00%
Final one-time transitioned income			$ (697,000)	$ (919,000)	$ (649,000)
Decrease in deferred tax assets		$ 11,273,000		11,273,000
Decrease in valuation allowance		(11,273,000)	(4,453,000)	(10,211,000)	(9,470,000)
U.S. federal income tax benefits			0	0	0
Increase valuation allowance associated with tax benefit	$ 3,391,000
Gross unrecognized tax benefits		1,676,000	$ 1,308,000	1,676,000	$ 1,663,000	$ 2,084,000
Accounting Standards Update 2016-09 [Member]
Income Taxes [Line Items]
Cumulative effect of retained earnings	$ 3,391,000
2017 Federal Tax Return [Member]
Income Taxes [Line Items]
Final one-time transitioned income				17,724,000
Foreign tax credits		$ 0		$ 0

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stockholders' Equity

12.	STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2019, 2,534 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2019			2018			2017
Risk-free interest rate⁽¹⁾		2.52	%		2.60	%		2.22	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		41	%		43	%		43	%
Expected life of stock options (in years)⁽²⁾		5			6			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2019, 2018 and 2017 was $5.19, $9.15 and $4.71, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2019			2018			2017
Total compensation cost during the year	$	1,161		$	2,163		$	2,045
Amounts capitalized into inventory during the year		(343	)		(420	)		(371	)
Amounts recognized in cost of products sold for amounts previously capitalized		405			396			276
Amounts charged against income	$	1,223		$	2,139		$	1,950

The aggregate intrinsic value of options exercised during the years ended December 31, 2019, 2018, and 2017 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $92, $2,314, and $35,631, respectively.

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2019		1,083			10.19
Granted		215			12.71
Exercised		(27	)		7.17
Expired		(41	)		8.68
Forfeited		(37	)		13.05
Outstanding on December 31, 2019		1,193		$	10.68		5.89	$	651
Vested or expected to vest as of December 31, 2019		1,193		$	10.68		5.89	$	651
Exercisable on December 31, 2019		896		$	9.79		4.99	$	630

As of December 31, 2019, there was $1,423 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.5 years.

Net cash proceeds from the exercise of stock options were $196, $1,701 and $31,675 for the years ended December 31, 2019, 2018, and 2017, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2019:

Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37 - $8.24		371		4.6	$	6.16		352	$	6.13
$8.87 - $14.95		657		6.1		10.82		432		10.08
$16.80 - $21.89		165		8.1		20.30		112		20.15
		1,193		5.9	$	10.68		896	$	9.79

The Stock Plan also permits us to grant restricted shares and restricted units of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,979, $6,357 and $2,705 related to restricted shares was recognized during the years ended December 31, 2019, 2018, and 2017, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2019		357			12.14
Granted		329			11.58
Vested		(212	)		10.30
Forfeited		(10	)		13.69
Issued and unvested, December 31, 2019		464		$	12.86
Issued and expected to vest, December 31, 2019		464		$	12.86

As of December 31, 2019, there was $3,200 of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.9 years.

In connection with the vesting of restricted shares during the years ended December 31, 2019, 2018 and 2017, we purchased and immediately retired 76, 171 and 130 shares with aggregate values of $949, $3,291 and $1,240, respectively, in satisfaction of minimum tax withholding and exercise obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share or income before taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $(83), $6,717 and $2,223 related to the PSUs was recognized during the years ended December 31, 2019, 2018 and 2017, respectively.

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2019		661			9.26
Granted⁽¹⁾		201			12.98
Performance adjustment⁽²⁾		168			12.98
Vested		(505	)		5.47
Issued and unvested, December 31, 2019		525		$	12.52
Issued and expected to vest, December 31, 2019		525		$	12.52

^1.

^{Grant activity for all PSUs disclosed at target.}

^2.

^{Reflects the performance adjustment based on actual performance measured at the end of the performance period.}

In connection with the vesting of performance stock units during the year ended December 31, 2019 and 2018, we purchased and immediately retired 213 and 20 shares with aggregate values of $2,763 and $301, respectively. No performance stock units vested in 2017.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2019, 2018 or 2017.

Credit Facility - Additional Information (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Line Of Credit Facility [Abstract]
Borrowings	$ 0	$ 0	$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories

	December 31,
	2019		2018
Raw materials	$	14,168	$	14,092
Work in process		643		544
Finished goods		8,344		8,252
	$	23,155	$	22,888

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

Use of Estimates

Supplemental Cash Flow Information

In 2019, 2018 and 2017, we paid income taxes of $10,611, $17,126 and $4,309, respectively.

As of December 31, 2019, 2018 and 2017, we had accruals for purchases of property and equipment of $660 , $964 and $ 449, respectively.

Investments

The following is a summary of our available-for-sale securities as of December 31, 2019 and 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At December 31, 2019, maturities of our available- for-sale securities were as follows:
Less than one year	$	80,754	$	163	$	(294	)	$	80,623
Greater than one year	$	33,403	$	108	$	(91	)	$	33,420

Accounts Receivable

Inventories

Property, Plant and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenue

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Deferred Revenue

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2019		2018		2017
OraQuick®	$	56,064	$	53,851	$	60,558
Oragene®		46,701		69,798		67,232
ORAcollect®		10,651		6,052		1,952
Intercept®		8,105		7,709		8,125
Microbiome laboratory services		6,104		1,563		1,223
Histofreezer® (through August 16, 2019)		5,702		8,983		10,312
OMNIgene® • GUT		5,226		4,193		2,072
Other products		9,520		13,279		10,514
Net product and service revenues		148,073		165,428		161,988

Royalty income		5,116		9,653		—
Research and development funding		851		4,951		4,387
Charitable support reimbursement		261		1,711		689
Grant funding		304		—		—
Other revenues		6,532		16,315		5,076

Net revenues	$	154,605	$	181,743	$	167,064

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2019		2018		2017
United States	$	107,279	$	136,847	$	121,458
Europe		11,752		11,062		11,827
Other regions		35,574		33,834		33,779
	$	154,605	$	181,743	$	167,064

Customer and Vendor Concentrations

Leases

Business Combinations and Contingent Consideration

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and


	•		discount rates used to determine the present value of estimated future cash flows.

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2019, 2018, and 2017, we incurred $524, $763, and $717, respectively, in advertising expenses.

Stock-Based Compensation

Income Taxes

Foreign Currency Translation

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2019		2018		2017
Net income	$	16,656	$	20,396	$	30,948
Weighted average shares of common stock outstanding:
Basic		61,675		61,112		59,050
Dilutive effect of stock options, restricted stock, and performance stock units		495		1,420		1,974
Diluted		62,170		62,532		61,024
Earnings per share:
Basic	$	0.27	$	0.33	$	0.52
Diluted	$	0.27	$	0.33	$	0.51

Accumulated Other Comprehensive Loss

Fair Value of Financial Instruments

Level 1:Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2019 and 2018.

Recent Accounting Pronouncements

Sale of Cryosurgical Business

12 Months Ended

Dec. 31, 2019

Discontinued Operations And Disposal Groups [Abstract]

Sale of Cryosurgical Business

4. SALE OF CRYOSURGICAL BUSINESS

On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical systems line of business to

a third party for $12,000. This business consisted of medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The products were sold in both the professional and OTC markets in North America, Europe, Central and South America and Australia. We also entered into a transition services agreement with CryoConcepts in which both parties agreed to provide certain transition services beginning after the closing. The Company recorded a gain on sale of business of $10,149 reflected in our statement of income for the year ended December 31, 2019. The gain includes the $12,000 of proceeds net of the fair value of the assets sold, which consisted entirely of inventory and fully-depreciated fixed assets, the legal fees associated with the transaction, and a value attributed to the transition services.

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 6,088	$ 8,926
Professional fees	2,769	1,541
Income taxes payable		1,447
Other	5,431	1,947
Accrued Expenses, Total	$ 14,288	$ 13,861

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended								12 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2019
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current			$ 112								$ 112
Revenues											154,605	$ 181,743	$ 167,064
Net income (loss)			2,438	$ 13,078	$ 4,398	$ (3,258)	$ 10,298	$ 8,096	$ 4,121	$ (2,119)	16,656	$ 20,396	$ 30,948
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price		$ 13,320
Acquisition-related costs											$ 639
Business acquisition contingent consideration, non-current		$ 32,400
Business combination contingent consideration expected payment period		3 years									2 years
Estimated fair value of contingent consideration		$ 4,350
Business acquisition contingent consideration			3,612								$ 3,612			$ 3,500
Revenues											5,152
Net income (loss)											(2,450)
Corebiome Inc. and Novosanis NV [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current			27,400								27,400
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Purchase price	$ 12,000
Acquisition-related costs											1,198
Business acquisition contingent consideration, non-current			$ 1,500								1,500
Estimated fair value of contingent consideration	0
Business acquisition contingent consideration	$ 0
Revenues											1,046
Net income (loss)											$ (47)
Business combination contingent consideration expected payment year											2020

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Schedule of Property, Plant and Equipment

	December 31,
	2019			2018
Land	$	1,118		$	1,118
Buildings and improvements		23,231			22,480
Machinery and equipment		33,568			29,017
Computer equipment and software		11,590			9,632
Furniture and fixtures		2,791			2,681
Construction in progress		4,923			2,168
		77,221			67,096
Less accumulated depreciation		(46,882	)		(42,797	)
	$	30,339		$	24,299

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,522	$ 2,623	$ 2,641

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome, Diversigen, and Novosanis acquisitions as if they had been consummated as of January 1, 2017. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2017.

	Year Ended December 31,
	2019		2018		2017

Revenue	$	158,576	$	190,487	$	173,554
Net income		16,806		19,448		27,436
Net income per share, basic		0.27		0.32		0.46
Net income per share, diluted		0.27		0.31		0.45

Corebiome Inc. and Novosanis NV [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Diversigen, Inc. [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,443
Total assets acquired		13,198
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,584
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,584

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ 185,850		$ 350,528	$ (14,220)	$ (150,458)
Beginning Balance, Shares at Dec. 31, 2016		56,001
Common stock issued upon exercise of options	31,670		31,670
Common stock issued upon exercise of options, Shares		4,413
Vesting of restricted stock	0	$ 0	0	0	0
Vesting of restricted stock, Shares		378
Purchase and retirement of common shares	(1,240)		(1,240)
Purchase and retirement of common shares, Shares		(130)
Compensation cost for restricted stock	2,705		2,705
Compensation cost for stock option grants	2,045		2,045
Compensation cost for performance stock units	2,223		2,223
NET INCOME	30,948				30,948
Currency translation adjustments	4,433			4,433
Unrealized gain (loss) on marketable securities	(553)			(553)
Ending Balance at Dec. 31, 2017	258,081		387,931	(10,340)	(119,510)
Ending Balance, Shares at Dec. 31, 2017		60,662
Adoption of ASU 2014-9	(75)				(75)
Common stock issued upon exercise of options	1,697		1,697
Common stock issued upon exercise of options, Shares		227
Vesting of restricted stock	0	$ 0	0	0	0
Vesting of restricted stock, Shares		578
Purchase and retirement of common shares	(3,592)		(3,592)
Purchase and retirement of common shares, Shares		(191)
Compensation cost for restricted stock	6,357		6,357
Compensation cost for stock option grants	2,163		2,163
Compensation cost for performance stock units	6,717		6,717
NET INCOME	20,396				20,396
Currency translation adjustments	(8,003)			(8,003)
Unrealized gain (loss) on marketable securities	(363)			(363)
Ending Balance at Dec. 31, 2018	283,378		401,273	(18,706)	(99,189)
Ending Balance, Shares at Dec. 31, 2018		61,276
Common stock issued upon exercise of options	$ 196		196
Common stock issued upon exercise of options, Shares	27	27
Vesting of restricted stock and performance stock units	$ 0	$ 0	0	0	0
Vesting of restricted stock and performance stock units, Shares		717
Purchase and retirement of common shares	(3,712)		(3,712)
Purchase and retirement of common shares, Shares		(289)
Compensation cost for restricted stock	2,979		2,979
Compensation cost for stock option grants	1,161		1,161
Compensation cost for performance stock units	(83)		(83)
NET INCOME	16,656				16,656
Currency translation adjustments	5,767			5,767
Unrealized gain (loss) on marketable securities	803			803
Ending Balance at Dec. 31, 2019	$ 307,145		$ 401,814	$ (12,136)	$ (82,533)
Ending Balance, Shares at Dec. 31, 2019		61,731

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 114,157	$ 113,803
Gross Unrealized Gains	271	0
Gross Unrealized Losses	(385)	(917)
Fair Value	114,043	112,886
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,632	23,096
Gross Unrealized Gains	0	0
Fair Value	24,632	23,096
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	89,525	90,707
Gross Unrealized Gains	271	0
Gross Unrealized Losses	(385)	(917)
Fair Value	89,411	$ 89,790
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	80,754
Gross Unrealized Gains	163
Gross Unrealized Losses	(294)
Fair Value	80,623
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	33,403
Gross Unrealized Gains	108
Gross Unrealized Losses	(91)
Fair Value	$ 33,420

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Year ended
	December 31, 2019
Operating Lease Cost	$	964
Finance Lease Cost
Amortization of right-of use assets		410
Interest on lease liabilities		36
Total Finance Lease Cost	$	446

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Year ended
	December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	937
Operating cash flows from financing leases		33
Financing cash flows from financing leases		442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		1,829
Right-of-use assets obtained in exchange for finance lease obligations		2,069

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	December 31, 2019
Operating Leases
Right-of-use assets	$	4,996

Current lease liabilities		1,032
Non-current lease liabilities		4,206
Total operating lease liabilities	$	5,238

Finance Leases
Right-of-use assets	$	1,951

Current lease liabilities		613
Non-current lease liabilities		1,372
Total finance lease liabilities	$	1,985

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.21
Weighted-average remaining lease term—finance leases	3.45

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.31	%
Weighted-average discount rate—finance leases	4.40	%

Schedule of Minimum Lease Payments by Period Expected

	Finance			Operating
2020		685			1,273
2021		556			1,214
2022		555			1,194
2023		325			759
2024		17			777
Thereafter		4			760
Total Minimum Lease Payments		2,142			5,977
Less: imputed interest		(157	)		(739	)
Present Value of Lease Liabilities	$	1,985		$	5,238

Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 30,339	$ 24,299
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	23,846	18,776
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	5,697	5,192
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 796	$ 331

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Net revenues	$ 154,605	$ 181,743	$ 167,064
Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	148,073	165,428	161,988
Product Revenues [Member] \| OraQuick [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	56,064	53,851	60,558
Product Revenues [Member] \| Oragene [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	46,701	69,798	67,232
Product Revenues [Member] \| ORAcollect [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	10,651	6,052	1,952
Product Revenues [Member] \| Intercept [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	8,105	7,709	8,125
Product Revenues [Member] \| Microbiome Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	6,104	1,563	1,223
Product Revenues [Member] \| Histofreezer (through August 16, 2019) [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	5,702	8,983	10,312
Product Revenues [Member] \| O M N I Gene G U T
Disaggregation Of Revenue [Line Items]
Net revenues	5,226	4,193	2,072
Product Revenues [Member] \| Other Products [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,520	13,279	10,514
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	6,532	16,315	5,076
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	5,116	9,653
Other [Member] \| Research and Development Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	851	4,951	4,387
Other [Member] \| Charitable Support Reimbursement [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	261	$ 1,711	$ 689
Other [Member] \| Grant Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 304

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	1,193
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.68
Number Exercisable, Options exercisable \| shares	896
Weighted-Average Exercise Price Per Share, Options exercisable	$ 9.79
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.37
Range of exercise prices, Upper Range Limit	$ 8.24
Number Outstanding, Options outstanding \| shares	371
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 7 months 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.16
Number Exercisable, Options exercisable \| shares	352
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.13
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.87
Range of exercise prices, Upper Range Limit	$ 14.95
Number Outstanding, Options outstanding \| shares	657
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.82
Number Exercisable, Options exercisable \| shares	432
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.08
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	16.80
Range of exercise prices, Upper Range Limit	$ 21.89
Number Outstanding, Options outstanding \| shares	165
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years 1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 20.30
Number Exercisable, Options exercisable \| shares	112
Weighted-Average Exercise Price Per Share, Options exercisable	$ 20.15

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Operating Leases
Right-of-use assets	$ 4,996
Current lease liabilities	1,032
Non-current lease liabilities	4,206
Total operating lease liabilities	5,238
Finance Leases
Right-of-use assets	1,951
Current lease liabilities	613
Non-current lease liabilities	1,372
Total finance lease liabilities	$ 1,985

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Schedule of Outstanding Non-cancelable Purchase Commitments

As of December 31, 2019, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2020		10,279
2021		20
2022		20
2023		18
2024		-
	$	10,337

Schedule of Base Salary for Continuing Employment Agreement

Under terms of employment agreements with certain employees, which extend through 2023, we are required to pay each individual a base salary for continuing employment with us as follows:

2020		3,110
2021		1,682
2022		460
2023		309
	$	5,561

Sale of Cryosurgical Business - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Aug. 16, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business	$ 10,149
Proceeds from sale of business	12,000
Cryosurgical Systems
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Consideration receivable from sale of business		$ 12,000
Gain on sale of business	10,149
Proceeds from sale of business	$ 12,000

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Lease cost		$ 1,461	$ 852
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

Business Combinations

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Business Combinations

3. BUSINESS COMBINATIONS

CoreBiome and Novosanis

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the year ended December 31, 2019, we incurred a total of $639 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income.

Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over the next three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculates the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $3,612 as of December 31, 2019. This change is a result of changes in our estimated revenue forecasts and an amendment to one of the agreements, entered into in October 2019, in which management agreed to settle the contingent consideration associated with one of the acquisition’s 2019 results for $3,500. As of December 31, 2019, we may pay up to an additional $27,400 of contingent consideration over the next two years.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment. For the year ended December 31, 2019, consolidated net revenues include combined revenues associated with the CoreBiome and Novosanis business of $5,152. Consolidated results from operations for the year ended December 31, 2019 included a net loss of $2,450 generated from the combined companies since the acquisition date.

Diversigen

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen, Inc. (“Diversigen”), pursuant to the terms of a merger agreement. We began operating this entity as of the November 8, 2019 closing date.

The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above.

During the year ended December 31, 2019, we incurred a total of $1,198 of acquisition related costs, including investment banking fees and accounting, legal and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income for the year ended December 31, 2019.

Pursuant to our acquisition agreements, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements. The estimated acquisition-date fair value of the acquisition-related contingent consideration was $0. The fair value of the contingent consideration obligation of $0 is a result of not achieving the defined revenue metrics.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,443
Total assets acquired		13,198
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,584
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,584

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of Diversigen. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The amortization of intangible assets is not deductible for income tax purposes.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed. Additional information, which existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from Diversigen primarily consist of microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our DNAG segment. For the year ended December 31, 2019, consolidated net revenues include revenues associated with

the Diversigen business of $1,046, and consolidated results from operations include a net loss of $47 generated since the acquisition date.

Unaudited Pro Forma Financial Information

	Year Ended December 31,
	2019		2018		2017

Revenue	$	158,576	$	190,487	$	173,554
Net income		16,806		19,448		27,436
Net income per share, basic		0.27		0.32		0.46
Net income per share, diluted		0.27		0.31		0.45

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Results of Operations

	2019 Results
	Three months ended
	March 31, 2019			June 30, 2019		September 30, 2019				December 31, 2019

Net revenues	$	30,122		$	38,826	$	35,989			$	49,668
Costs and expenses		33,933			33,541		22,937	(1	)		45,583
Operating income (loss)		(3,811	)		5,285		13,052	(1	)		4,085
Other income, net		524			524		1,195				477
Income (loss) before income taxes		(3,287	)		5,809		14,247				4,562
Income tax expense		(29	)		1,411		1,169				2,124
Net income (loss)	$	(3,258	)	$	4,398	$	13,078			$	2,438
Earnings (loss) per share
Basic	$	(0.05	)	$	0.07	$	0.21			$	0.04
Diluted	$	(0.05	)	$	0.07	$	0.21			$	0.04


	2018 Results
	Three months ended
	March 31, 2018			June 30, 2018		September 30, 2018				December 31, 2018

Net revenues	$	41,987		$	43,625	$	45,885			$	50,246
Costs and expenses		42,485			38,067		35,028				37,734
Operating income		(498	)		5,558		10,857				12,512
Other income, net		412			736		510				1,629
Income before income taxes		(86	)		6,294		11,367				14,141
Income tax expense		2,033			2,173		3,271				3,843
Net income	$	(2,119	)	$	4,121	$	8,096			$	10,298

Earnings per share
Basic	$	(0.03	)	$	0.07	$	0.13			$	0.17
Diluted	$	(0.03	)	$	0.07	$	0.13			$	0.16

⁽¹⁾ Includes a $10,149 gain associated with the sale of the cryosurgical business, which was recorded as a reduction of operating expenses in the indicated period.

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest [Abstract]
United States									$ 3,106	$ (11,728)	$ 2,270
Foreign									18,225	43,444	38,762
Income before income taxes	$ 4,562	$ 14,247	$ 5,809	$ (3,287)	$ 14,141	$ 11,367	$ 6,294	$ (86)	$ 21,331	$ 31,716	$ 41,032

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 937
Operating cash flows from financing leases	33
Financing cash flows from financing leases	442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations	1,829
Right-of-use assets obtained in exchange for finance lease obligations	$ 2,069

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Changes in Goodwill

The changes in goodwill are as follows:

	December 31,
	2019		2018
Balance as of January 1		18,521		20,083
Goodwill acquired during the year		16,811		—
Change related to foreign currency translation		869		(1,562	)
Balance as of December 31	$	36,201	$	18,521

Summary of Intangible Assets

Intangible assets consist of the following:

			December 31, 2019
	Amortization Period (Years)		Gross		Accumulated Amortization			Net

Customer relationships		10	$	14,731	$	(8,054	)	$	6,677
Patents and product rights		10		5,400		(5,158	)		242
Developed technology	7-10			12,410		(7,982	)		4,428
Tradename	5-15			5,553		(2,226	)		3,327
			$	38,094	$	(23,420	)	$	14,674

			December 31, 2018
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	9,186	$	(6,532	)	$	2,654
Patents and product rights		10		5,400		(4,708	)		692
Developed technology		7		7,135		(7,135	)		-
Tradename		15		3,521		(1,730	)		1,791
			$	25,242	$	(20,105	)	$	5,137

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2020		2,619
2021		2,375
2022		1,470
2023		1,470
2024		1,430
Beyond		5,310
	$	14,674

Inventories

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventories

5.	INVENTORIES:

	December 31,
	2019		2018
Raw materials	$	14,168	$	14,092
Work in process		643		544
Finished goods		8,344		8,252
	$	23,155	$	22,888

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Net revenues	$ 154,605	$ 181,743	$ 167,064
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	107,279	136,847	121,458
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,752	11,062	11,827
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 35,574	$ 33,834	$ 33,779

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance as of January 1	$ 1,676	$ 1,663	$ 2,084
Additions for tax positions of prior periods	4	44
Reductions for tax positions of prior periods	(372)	(31)	(421)
Balance as of December 31	$ 1,308	$ 1,676	$ 1,663

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	754,000	$ 721,000	$ 617,000
Value of the assets associated with the plan	3,519,000	3,884,000
Total obligation under plan	3,519,000	3,884,000
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2,000
Contributed to plan, net of forfeitures	$ 184,000	$ 163,000	$ 145,000

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%	34.00%
Deemed repatriation tax			10.90%	7.80%
GILTI tax		16.90%	22.20%
Statutory rate change, deferred tax impact				29.40%
Nondeductible executive compensation		0.40%	4.80%
Impact of share-based payment awards		(5.30%)	0.60%	(16.00%)
Tax effect of foreign items		4.50%	6.80%	(8.30%)
State income taxes, net of federal benefit		4.00%	2.80%	(1.10%)
Nondeductible transaction costs		$ 1,600
Nondeductible expenses and other		(0.70%)	(1.20%)	1.90%
Change in valuation allowance, federal and state		(20.50%)	(32.20%)	(23.10%)
Effective tax rate		21.90%	35.70%	24.60%